erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.
editor's six of the best
.
.
.
edition
international editions:
.
the publication�s purpose is to be a "force for good and a platform for much needed change and to generate critical debate".
.
.
our partners
.
maslow's ideas deserve to be better understood so they can be developed and built upon. by alex fradera
.
.
.
.
.